Publications by authors named "Satoshi Katakami"

Article Synopsis
  • The study investigates the combined efficacy of afatinib, an EGFR-tyrosine kinase inhibitor, and bevacizumab, a VEGF inhibitor, in patients with EGFR-mutant non-small cell lung cancer who have become resistant to osimertinib.
  • Out of 28 enrolled patients, the combination treatment resulted in a 17.9% response rate and an overall disease control rate of 78.6%, with a median duration of response of 9 months.
  • The analysis of rebiopsied samples identified various resistance mechanisms, revealing that certain mutations (like C797S and uncommon EGFR mutations) were associated with better responses, while patients with T790M
View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated the long-term impacts of tofogliflozin, an SGLT2 inhibitor, on atherosclerosis and key health markers in type 2 diabetes patients without cardiovascular disease.
  • Over a 2-year period, both tofogliflozin and conventional treatments reduced carotid intima-media thickness, but with no notable difference between the two groups.
  • Tofogliflozin showed advantages in improving blood sugar, cholesterol, BMI, waist circumference, and blood pressure compared to conventional treatment, while safety metrics were not significantly different between groups.
View Article and Find Full Text PDF
Article Synopsis
  • Zoledronic acid (ZA) is effective in reducing skeletal-related events (SREs) in lung cancer patients with bone metastases, but the ideal dosing interval remains unclear.
  • A randomized trial compared 4 mg of ZA given every four weeks versus every eight weeks, assessing the time to first SRE and other health indicators over one year.
  • Results showed no significant differences in SRE occurrence or other health measures between the two dosing groups, suggesting an eight-week interval is a safe and viable option for treatment.
View Article and Find Full Text PDF

Background: Tofogliflozin, an SGLT2 inhibitor, is associated with favorable metabolic effects, including improved glycemic control and serum lipid profile and decreased body weight, visceral adipose tissue, and blood pressure (BP). This study evaluated the effects of tofogliflozin on the brachial-ankle pulse wave velocity (baPWV) in patients with type 2 diabetes (T2DM) without a history of apparent cardiovascular disease.

Methods: The using tofogliflozin for possible better intervention against atherosclerosis for type 2 diabetes patients (UTOPIA) trial is a prospective, randomized, open-label, multicenter, parallel-group, comparative study.

View Article and Find Full Text PDF

Background: This study aimed to investigate the preventive effects of tofogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT).

Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofogliflozin treatment group (n = 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n = 171).

View Article and Find Full Text PDF

Purpose: The epidermal growth factor receptor (EGFR) tyrosine kinase has been an important target for non-small-cell lung cancer. Several EGFR tyrosine kinase inhibitors (TKIs) are currently approved, and both gefitinib and erlotinib are the most well-known first-generation EGFR-TKIs. This randomized phase III study was conducted to investigate the difference between these two EGFR-TKIs.

View Article and Find Full Text PDF